Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Mio, Lee, Katherine, Jeon, Caleb, Sekhon, Sahil, Afifi, Ladan, Yan, Di, Lee, Kristina, Bhutani, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574739/
https://www.ncbi.nlm.nih.gov/pubmed/28639011
http://dx.doi.org/10.1007/s13555-017-0187-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574739/
https://www.ncbi.nlm.nih.gov/pubmed/28639011
http://dx.doi.org/10.1007/s13555-017-0187-0

Ejemplares similares